Immunogenicity and safety of an inactivated hepatitis A vaccine in Taiwanese adults and children

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 31, Issue 1, 2000, Pages 29-36

  Lee, Chin Yun ^a   Huang, Li Min ^a   Lee, Ping Ing ^a   Chiu, Hsiu Hui ^b   Dumas, Rafaele ^c,e   Milcamps, Bruno ^c   Lin, Wendy ^d  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c Pasteur Merieux Connaught Intl   (France)

^d CAG Sector of Agilent Technologies Taiwan Ltd   (Taiwan)

^e Clinical Development Department   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; HEPATITIS ANTIBODY; INACTIVATED VACCINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CHILD; CLINICAL TRIAL; FEMALE; HEPATITIS A; HEPATITIS A VIRUS; HUMAN; IMMUNIZATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MALE; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; TAIWAN;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPATITIS ANTIBODIES; HEPATOVIRUS; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; MALE; TAIWAN; VACCINES, INACTIVATED;

EID: 0034156619     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LO, USA: September 15-18. Washington DC: American Society for Microbiology, 1996: 176.
2. Bell BP, Shapiro CN, Alter MJ, et al. The diverse patterns, of HA epidemiology in the United States-implications for vaccination strategies. J Infect Dis 1998; 178: 1579-84.
3. Berger R, Just M. Vaccination against hepatitis A: control 3 years after the first vaccination. Vaccine 1992; 10: 295.
4. Brewer MA, Edwards KM, Decker M. Who should receive hepatitis A vaccines. Pediatr Infect Dis J 1995; 14: 258-60
5. Cabahug OT. Prevalence of HA antibodies among Filipino children and adolescents residing in Manila. UERM J Med 1992; 1: 71-4.
6. Castillo de Febres O, Chacon de Petrola M, Casanova de Escalona L, et al. Safety, immunogenicity and antibody persistence of an inactivated hepatitis A vaccine in 4 to 15 year old children. Vaccine 2000; 18: 656-64.
7. Centers for Disease Control. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR 1996; 45(RR-15): 1-30.
8. Chan CY, Lee SD, Yu MI, Wang YJ, Chang FY, Lo KJ. Long term follow-up of hepatitis A vaccination in children. Vaccine 1999; 17: 369-72.
9. Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, Andre FE. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995; 171 (suppl), S44-9.
10. Craig AS, Sockwell DC, Schaffner W, et al. Use of hepatitis A vaccine in a community-wide outbreak of hepatitis A. Clin Infect Dis 1998; 27: 531-5.
11. Dentico P, Ciavarella N, Scaraggi FA, et al. Long-term immunogenicity and safety of an inactivated hepatitis A vaccine in haemophiliac patients. Haemophilia 1996; 2: 37-40.
12. Fisch A, Cadilhac P, Vidor E, Prazuck T, Dublanchet A, Lafaix C. Immunogenicity and safety of a new inactivated hepatitis A vaccine: a clinical trial with comparison of administration route. Vaccine 1996; 14: 1132-6.
13. Forbes A, Willimas R. Increasing age - an important adverse prognostic factor in hepatitis A virus infection. JR Coll Physicians Lond 1988; 22: 237-9.
14. Garin D, Vidor E, Wallon M, et al. Good immunogenicity of GMB strain inactivated hepatitis A vaccine in healthy male adults. Vaccine 1995; 13: 220-4.
15. Goilav C, Zuckerman J, Lafrenz M, et al. Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study. J Med Virol 1995; 46: 287-92.
16. Goilav C, Zuckerman J, Lafrenz M, Vidor E, et al. Persistence of antibodies after inactivated Hepatitis A vaccines in a comparative study. J Infect 1997; 34: 158.
17. Gonzales J, Fay O, Canero Velasco M, et al. HAV infection in children in Argentinean population [Abstract A57]. IX Triennial International Symposium on Viral Hepatitis and Liver Disease. Rome, Italy, 1996.
18. Gonzales J, Fay O, Canero-Velaso MC, et al. Infeccion por virus de hepatitis A (HAV) en ninos en Argentina. Ensayo piloto. Acta Gastroent Latinoamer 1997; 27: 331-4.
19. Gust ID. Epidemiological patterns of HA in different parts of the world. Vaccine 1992; 10: S56-8.
20. Horng YC, Chang MH, Lee CY, Safary A, André FE, Chen DS. Safety and immunogenicity of hepatitis A vaccine in healthy adult volunteers. J Gastroenterol Hepatol 1993a; 8: 338-41.
21. Horng YC, Chang MH, Lee CY, Safary A, André FE, Chen DS. Safety and immunogenicity of hepatitis A vaccine in healthy children. Pediatr Infect Dis J 1993b; 12: 359-62.
22. Innis BL, Snitbhan R, Kunasol T, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994; 271: 1328-34.
23. Iriart M, Joaquin W, Lamy P, et al. Hepatitis A virus prevalence in Argentine children [Abstract H3]. ICAAC Toronto, Canada, 1997.
24. Keefe EB, Iwarson S, McMahon BJ, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998; 27: 881-6.
25. Koff RS. Hepatitis A. Lancet 1998; 351: 1643-9.
26. Koff RS. The case for routine childhood vaccination against hepatitis A. N Engl J Med 1999; 340: 644-5.
27. Kunasol P, Cooksley G, Chan VF, et al. Hepatitis A virus: declining seroprevalence in children and adolescents in Southeast Asia. Southeast Asian J Trop Med Public Health 1998; 29: 255-62.
28. Lea A, Balfour J. Virosomal hepatitis A vaccine (strain RG-SB) Bio Drugs 1997; 7: 232-48.
29. th Interscience Conference on Antimicro-biological Agents and Chemotherapy, San Francisco, CA, Whashington, DC: American Society for Microbiology, 1995.
30. Maiwald H, Jilg W, Bock H, Loscher T, von Sonnenburg F. Long-term persistence of anti-VHA antibodies following active immunization with hepatitis A vaccine. Vaccine 1997; 15: 346-8.
31. Margolis HS, Shapiro CN. Considerations for the development of recommendations for the use of hepatitis A vaccine. J Hepatol 1993; 18(supp 12): S56-S60.
32. th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 28 to October 1, 1997. Washington DC: Ameriacan Society for Microbiology, 1997: 298.
33. McMahon B, Beller M, Williams J, Schloss M, Tanttila H, Bulkow L. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arc Ped Adoles Med 1996; 150: 733-9.
34. Nalin DR, Kuter BJ, Brown L, et al. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: An overview. J Hepatol 1993; 18: S51-5.
35. Nalin DR. VAQTA™ Hepatitis A vaccine, purified inactivated. Drugs Future 1995; 20: 24-9.
36. Poovorawan Y, Theamboonlers A, Vimolkej T, Chongsrisawat V. Prevalence of infection with hepatitis A virus among primary-school children in Bangkok, Thailand. Ann Trop Med Parasitol 1997a; 91: 119-20.
37. Poovorawan Y, Vimolkej T, Chongsrisawat V, Theamboonlers A, Chumdermpadetsuk S. The declining pattern of seroepidemiology of hepatitis A virus infection among adolescents in Bangkok, Thailand. Southeast Asian J Trop Med Public Health 1997b; 28: 154-7.
38. Prikazsky V, Olear V, Cernoch A, Safary A, André FE. Interruption of an outbreak of hepatitis A in two villages by vaccination. J Med Virol 1994; 44: 457-9.
39. Richtmann R, Chaves RL, Mendonca JS, et al. Immunogenicity and efficacy of a killed hepatitis A vaccine in day care center children. J Med Virol 1996; 48: 147-50.
40. nd ed. 1997: 571-85.
41. Totos G, Papaevangelou G. Persistence of vaccine-induced antibodies for hepatitis a virus. Vaccine 1994; 12: 475.
42. Tsen KT, et al. Prevalence rate of HAV antibody in children < 10 years J Formos Med Assoc 1991; 90: 138-40.
43. Van Damme P, Thoelens S, Cramm M, Groote de K, Safary A, Meheus A. Inactivated hepatitis A vaccine;: reactogenicity, immunogenicity and long-term antibody persistence. J Med Virol 1994; 44: 446-51.
44. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338: 286-90.
45. Vidor E, Fritzell B, Plotkin S. Clinical development of a new inactivated hepatitis A vaccine. Infection 1996a; 24: 447-58.
46. Vidor E, Xueref C, Blondeau C, et al. Analysis of the antibody response in humans with a new inactivated hepatitis A vaccine. Biologicals 1996b; 24: 235-42.
47. Villarejos VM, Serra J, Anderson-Visona K, Mosley JW. Hepatitis A virus infection in households. Am J Epidemiol 1982; 115: 577-86.
48. Werzberger A, Kuter B, Nalin D. Six years' follow up after hepatitis A vaccination [letter]. N Engl J Med 1998; 338: 1160.
49. Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992; 327: 453-7.
50. Wiedermann G, Ambrosch F, André FE, Hondt d' E, Delem AD, Safary A. Persistence of vaccine-induced antibody to hepatitis-A virus. Vaccine 1992; 10: S129-31.
51. Wiens B, Bohidar N, Pigeon J, et al. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA™. J Med Virol 1996; 49: 235-41.
52. World Health Organization. Public health control of hepatitis A: memorandum from a WHO meeting. Bull WHO 1995; 73: 15-20.
53. Wu JS, Lu CF, Wu LZ, et al. Changing seroepidemiology of hepatitis A virus infection between two regions in Taiwan differing in socioecomomic status. J Formas Med Assoc 1993; 92: 812-5.